BIOPHARMACEUTICAL CMO AND CRO MARKET ANALYSIS

Biopharmaceutical CMO and CRO Market, By Source (Mammalian and Non-mammalian), By Service (Contract Manufacturing and Contract Research), and By Product (Biologics and Biosimilars), and By Geography (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)

Published In : Jun 2023
Code : CMI5933
Pages :160
Formats :
Excel and PDF
Industry : Medical Devices

Market News

Global Biopharmaceutical CMO and CRO Market: Key Developments

In February 2023, Lunaphore and Sirona Dx announced a strategic collaboration in which Sirona Dx will become the first CRO to offer Lunaphore’s flagship COMET spatial biology platform. A COMET will complement Sirona Dx’s portfolio of research service offerings to meet the needs of researchers and biopharma teams across various disciplines.

In March 2022, Meadowhawk Biolabs, Inc., a biotechnology and pharmaceutical CRO, announced the launch of its operations in the Boston and San Francisco areas.

In March 2022, Sterling Pharma Solutions UK, a global contract development and manufacturing organization (CDMO), announced the acquisition of Novartis Ringaskiddy Ltd.). Sterling acquired the 111-acre site, which includes three API manufacturing buildings, as well as facilities to support the development and scale-up in line with Sterling’s core business focus.